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MAPK-related signatures were downregulated upon MEKi treatment, while 
pathways related to upstream MAPK activators (including FGFR, NTRK 
and TGFB pathways) were upregulated, in both proliferating and senescent 
DKFZ-BT66. Genes regulated by the MAPK pathway and involved in OIS-
SASP were identified by analyzing genes differentially regulated between 
proliferating and senescent DKFZ-BT66, and modulated upon MEKi treat-
ment. Conclusion: This data suggests that MAPKi reverses OIS in senes-
cent PA cells, while inducing the activation of MAPK upstream regulators 
in proliferating and senescent PA cells, identifying putative co-targets that 
could help prevent growth rebound upon MAPKi withdrawal. Further-
more, the identification of the MAPK-related OIS-SASP genes provide in-
sight about the regulation of OIS-SASP by the MAPK pathway. Validation 
of this data with the ongoing phospho-proteomic analysis and in primary 
samples is needed.
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Background: The BRAF V600E mutation occurs in ~ twenty percent of 
histologically diverse pediatric gliomas and is the second most common mu-
tation in pediatric low-grade gliomas (LGG). BRAF V600E expression in 
LGG with balanced CDKN2A is associated with a higher rate for progres-
sion than for BRAF V600E wildtype tumors, and despite adjuvant therapy, 
consisting of resection, radiation and chemotherapy. Progression invari-
ably occurs in BRAF V600E mutant CDKN2A deleted gliomas, marking a 
high-risk group. Here, we aim to overcome the lack BRAF V600E mutant 
glioma models that allow for studies of stem and progenitor cells and the 
immune system ability to understand progression. Methods: We develop 
novel immunocompetent, stem and progenitor cell-based mouse models 
for BRAF mutant gliomas, including genetically engineered mouse models 
(GEMMs), orthotopic glioma models derived from gliomas in GEMMs 
as well as in vitro models of those tumors. BRAF mutant mouse brains 
and cells were analyzed by immunofluorescence staining, flow cytometry, 
mass cytometry and RNA sequencing.  Results: Ongoing model develop-
ment studies indicate that BRAF V600E mutant gliomas in murine brain 
exhibit very similar neuroanatomical preferences to human gliomas. The 
BRAF V600E mutation exacerbates the heterogenous cell cycling pat-
tern of normal neural stem and progenitors and expands a symmetrically 
dividing progenitor population. Cellular plasticity rather than cellular lin-
eage hierarchy drives the generation of a therapy resistant stem cell pool. 
Transcriptomic analyses of neuroglial stem cells with induced BRAF V600E 
expression provide insights into mechanisms for neoplastic transformation 
and progression. Conclusion: Analyses of two independent BRAF V600E 
mutant mouse models provide novel insights into the role for tumor in-
trinsic factors, such as plasticity and stemness, and the tumor microenvir-
onment in progression.
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Background: Low-grade gliomas (LGGs) arising in children with neuro-
fibromatosis type 1 (NF1) are usually not biopsied. To identify secondary 
genetic alterations or molecular features that may contribute to pathogenesis 
and correlate with clinical behavior, we initiated a comprehensive molecular 
and clinical analysis of pediatric NF1-LGGs.  Methods: NF1-LGGs were 
analysed by whole-genome sequencing (31), targeted gene panel sequencing 
(9), RNAseq transcriptomal profiling (33) and genome-wide DNA methy-
lation analysis (67). Clinical annotation was available for 48 subjects. Re-
sults: Most LGGs harbored bi-allelic NF1 inactivation as the sole genetic 
abnormality, but 11% had additional alterations (FGFR1 mutation, n=3; 
PIK3CA mutation, n=2; homozygous 9p21 deletion, n=2; MYB:QKI fusion, 
n=1; SETD2 mutation, n=1; EGFR amplification, n=1). FGFR1 mutation 
conferred additional growth advantage in multiple complementary murine 
Nf1 models. 88% of NF1-LGGs resembled sporadic pilocytic astrocytoma 
(PA) by methylation, higher than that based on histology. Non-PA methy-
lation patterns included low-grade glial/glioneuronal tumors, rosette-
forming glioneuronal tumors, MYB/MYBL1-altered glioma, and high-grade 
astrocytoma with piloid features (2 tumors histologically diagnosed as 
LGG). In total, 18% of samples were classified as non-PA and/or harbored 
an additional non-NF1 mutation. Non-PA methylation class tumors were 
more likely to harbor an additional non-NF1 mutation (p=0.005). 7.7% of 
optic pathway hypothalamic gliomas (OPHGs) had other mutations or were 
not classified by methylation as PA, compared with 20.6% of NF1-LGGs 
arising elsewhere. There was no difference based on age for the presence 
of an additional non-NF1 mutation or non-PA methylation class. Conclu-
sions: Given the overall low occurrence of non-NF1 mutations or non-PA 
methylation class tumors in this series, routine clinical biopsy of typically-
appearing NF1-LGG may not be indicated, particularly for children with 
OPHG. Biopsy should be considered for non-OPHG tumors refractory to 
conventional treatment. As additional agents are developed and treatment 
strategies evolve, the rationale for biopsy of NF1-LGG may become stronger.
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Introduction: Pediatric pilocytic astrocytomas (PA) are the most 
common pediatric central nervous system tumor. Surgical resection is the 
primary treatment for PA with five-year survival rates up to 95%. Des-
pite a favorable prognosis, our understanding about the prognostic value 
of histopathological findings, such as histopathologic qualifier* or BRAF 
alterations is evolving. Methods: Patients treated for a WHO grade 1 PA at 
Washington University in St. Louis/St. Louis Children’s Hospital were ana-
lyzed for clinical details, including pathology diagnosis (*histopathologic 
qualifier refers to designations in the diagnosis such as “WHO Grade 
I  pilocytic astrocytoma with increased proliferative index”). BRAF alter-
ations include gene fusions and point mutations.  Results: 224 patients 
were analyzed (51% female, mean age 9.6  years). Tumors were located 
in the cerebellum/fourth ventricle (50%), optic pathway/hypothalamus 
(15%), brainstem (12%), and cerebral cortex (11%). BRAF alterations 
were identified in 55/77 patients (71.4%) and additional histopathologic 
qualifiers were present in 27/220 patients (12.3%). 196 patients (87.5%) 
underwent surgical treatment and 22 (9.8%) had biopsy alone. 45 patients 
(22%) displayed tumor progression or recurrence after resection. The pres-
ence of a histopathologic ‘qualifier’ in the topline or BRAF alteration was 
not associated with tumor progression or recurrence (p=0.36, p=0.77). 
Ki-67 proliferative indices were not predictive of progression or recurrence 
(p=0.94), including when controlling for extent of resection and adjuvant 
therapy. BRAF alterations, specifically KIAA1549 fusions, were associated 
with cerebellar/fourth ventricular tumor location (p<0.001) and younger 
patient age (p=0.03). Extent of resection was the only predictor of outcome 
identified in this study; patients with gross total resection had significantly 
lower rates of progression and recurrence (p<0.0001). Conclusion: BRAF 
alterations and histopathologic qualifiers were not associated with tumor 
progression or recurrence in pediatric PA, although BRAF fusions were 
more common in tumors located in the cerebellum/fourth ventricle and in 
younger patients.
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